Compare Aurora Cannabis Inc (ACB) vs Infosys Limited (INFY) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

INFY trades at $10.88, down 2.51% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 16.44% and ROE of 31.57% for 2025, while recent earnings have mostly beaten expectations. Analyst consensus is a 'Hold' with a $13.18 price target, suggesting potential upside. Recent news highlights multiple AI collaborations, such as with Sentara and GlobalFoundries, indicating strategic focus on AI-driven growth.

The outlook for INFY is mixed; fundamentals remain solid with steady revenue growth and high profitability, but technical indicators and sector-wide demand concerns pose near-term risks. The stock presents a value opportunity given its low P/E of 13.6, though investors face volatility from competitive pressures and macroeconomic headwinds affecting IT spending.